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Abstract. Although clinical use of amiodarone is supposedly well-known since the drug has been in use for over fifty 
years, there have been some concerns that it is often used inappropriately. This paper aims to describe clinical and 
adverse events observed in patients treated in Coronary Care Unit and to check if the drug was being used in proper 
indication and dose. Also, the purpose of this survey was to determine whether the medical staff is familiar enough 
with adverse events and right indications of amiodarone administration. This qualitative study was based on three 
methods: interview with physicians operating in Coronary Care Unit, insight into patient files and observation of the 
amiodarone prescription. Five physicians operating in Coronary Care Unit were interviewed and patient files of seven 
patients have been observed. Amiodarone prescription was observed by making rounds together with physicians. 
Several problems regarding amiodarone administration have been established. Amiodarone was often diluted in 
physiological solution instead of 5% glucose solution and it was administered via peripheral vein, not the central one. 
Physicians are using amiodarone more often than they are supposed to, mainly due to lack of other antiarrhythmic 
agents. It was also noticed that medical staff do not strictly follow the guidelines for atrial fibrillation treatment, often 
using amiodarone as the first choice antiarrhythmic. Finally, physicians are not fully familiar with adverse events of 
amiodarone, especially with acute adverse events. It was concluded that inappropriate use is present in some cases. 
Thus, physicians should follow guidelines more carefully when prescribing the drug and additional education should 
be implemented. 
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Introduction 

 
Amiodarone is one of the most common drugs used to 
treat arrhythmias. According to Trappe, Brandts and 
Weismueller, typical arrhythmias in intensive care patients 
are atrial fibrillation (AF), atrial flutter, AV-nodal reentry 
tachycardia with rapid ventricular response, atrial ectopic 
tachycardia, and pre-excitation syndromes combined with 
atrial fibrillation or ventricular tachyarrhythmia. Immediate 
DC-cardioversion in all patients with unstable 
hemodynamics is indicated, while conversion to sinus 
rhythm is possible using antiarrhythmic drugs. In their 
opinion, short-term intravenous administration of 
amiodarone, as superior antiarrhythmic agent, is absolutely 
necessary in critically ill patients with recent onset atrial 
fibrillation
 
[1]. Rhythm control and rate control 
management strategies are defined for treatment of atrial 
fibrillation and flutter as the most frequent arrhythmias in 
emergency department. Amiodarone may be used for both 
cardioversion and heart rate control [2]. 
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Amiodarone has been developed in 1960s as a 
coronary vasodilator (with 13-year-long period of 
investigation [3]), which brings us to conclusion that 
amiodarone is a drug with long term usage. Amiodarone is 
currently used as antiarrhythmic agent for treatment of a 
variety of arrhythmias but there have always been concerns 
about its side effects. Mild adverse events are often seen in 
patients treated with amiodarone, but serious life-
threatening adverse events are also possible. This is the 
reason why systematic interdisciplinary follow-up protocol 
for outpatients treated with amiodarone is necessary  
[4]. One of the most severe systemic side effects of 
amiodarone chronic use is pulmonary toxicity which may 
lead to death. This is the reason why administration of 
amiodarone in intensive care unit should not last more than 
24/48h [5].
 
Extent and speed of onset of pulmonary 
damage is linked with severity of amiodarone-introduced 
pulmonary toxicity
 
[6, 7]. Special care is needed when 
amiodarone is prescribed because its administration may 
increase the risk of acute pancreatitis [8]. Thyroid 
dysfunction, corneal micro deposits, gastrointestinal 
problems and photosensitivity are also linked with 
amiodarone use, but this is not relevant to acute 
intravenous administration in intensive care. If thyroid 
dysfunction is indicated, collaboration between 
cardiologist and endocrinologist is mandatory [9]. Due to 
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possibility of intracardiac thrombus formation, conversion 
of AF should not be attempted 48h after onset without 
anticoagulation or transesophageal echocardiography [10]. 
Amiodarone is well tolerated in patients with both normal 
and impaired left ventricular systolic function [11]. Drug-
drug interactions are also observed where the most 
important are between digoxin and warfarin. When 
amiodarone is administered with other QT prolonging 
drugs, especially class 1A antiarrhythmics or in the 
presence of hypokalemia, torsades de pointes mostly 
occurs
 
[5]. 
Arrigo, Bettex and Rudiger recommend treatment of 
AF in intensive care unit setting with substances with a 
low risk profile and short half-life, such as beta blockers, 
while amiodarone is indicated in cases of contraindications 
or inefficacy of the initial treatment. Compared to beta 
blockers and calcium channel blockers, amiodarone has 
less negative inotropic effects and is safer for patients 
with structural heart disease. Long half-life and potential 
severe side effects are limiting its usage in intensive care 
unit. It is up to clinician to decide which agent he will use 
in critically ill patient based on efficiency/risk ratio
 
[12]. 
According to recent research where amiodarone, as 
preferential antiarrhythmic drug, was compared with non-
amiodarone antiarrhythmic drugs, amiodarone was not 
supported as a drug of choice in patients with left 
ventricular hypertrophy [13]. According to Brendorp, 
Pedersen, Torp-Pedersen, Sahebzadah and Køber, beta-
blockers are the first line therapy in patients at high risk 
of sudden death while amiodarone is favorable only in 
patients with heart failure [14]. Collected data from the 
research on adverse effects in randomized placebo-
controlled trials has shown that treatment with amiodarone 
for the prophylaxis of sudden cardiac death has less 
favorable net clinical benefit. Treatment with amiodarone 
in this setting should be used only in selected cases [15]. 
The term unreasonable use of the drug means it is 
being used beyond the protocol and thus costs of 
treatment are increasing but without improvement of 
patient condition or shortening hospitalization period. 
According to Kosińska and Brandy, amiodarone was 
potentially inappropriately prescribed in 7.47% of 
geriatric patients in Poland [16]. Napolitano, Izzo, Di 
Giuseppe and Angelillo‟s survey has shown that 
amiodarone was potentially inappropriately prescribed 
in 19.1% of cases of elderly patients in Italy with 24.9% 
of potentially inappropriate doses [17]. 
Clinical trials with amiodarone have been conducted 
for many years and will likely continue in the future [18]. 
Obviously, doubts about administration of amiodarone 
are present. In this paper, we wanted to provide one more 
piece of evidence to reduce the dilemma. Research was 
done, including interviews with physicians from coronary 
care department and observation of patients. Scientific 
method was used to reach conclusions with general 
procedure consisting of six steps: 1- State the problem, 2- 
Formulate the hypothesis, 3- Design the experiment or 
survey, 4- Make observations, 5- Interpret the data and 6- 
Draw conclusions [19]. 
Material and Methods 
This qualitative study was based on three methods: 
interview with physicians operating in Coronary Care 
Unit of Cardiology Department, University Hospital 
Center “Bezanijska Kosa“ in Belgrade, Republic of 
Serbia, insight into patient files and observation of the 
amiodarone prescription.  
Starting from January of 2015
th 
five physicians 
operating in Coronary Care Unit were interviewed using 
semi-structured interview. Nineteen questions were asked 
and anticipated time for conversation was twenty minutes. 
Before the study, the Head of Cardiology Department and 
the Director of the Hospital were contacted personally to 
present the study protocol and to obtain their approval to 
conduct the survey. Also, the study design and the Head 
of Department‟s statement have been submitted to the 
Ethics and Scientific Committee of the Hospital and their 
approval was obtained. Interviews were held in person 
with doctors at beforehand agreed time. Questions were 
asked from the prepared paper form and answers were 
recorded by audio device. The paper form was signed by 
an examinee (physician) as consent that interview will be 
recorded. 
Beside interviews with the above-mentioned staff, 
records of seven patients hospitalized in Coronary Care 
Unit and prescribed with amiodarone were used as a 
source of the data. For each patient being studied, the 
data included age, sex, ethnic affiliation, weight and 
height of the patient, followed by the history of disease 
with onset, type of arrhythmia, and other cardiac and 
non-cardiac illnesses. In addition to this, the patient 
records included concomitant medication, duration, 
dose and route of amiodarone administration, adverse 
reactions (if any) and how they have been solved (by 
which agent) as well as outcome of the therapy. 
Finally, the third part of the study was observation 
of amiodarone prescription by making ward-rounds 
together with physicians. The main objective of the 
third part is to recognize why amiodarone is prescribed, 
particularly paying attention to indication, dose, route 
and duration of amiodarone administration. 
Results 
Interview was conducted with five medical doctors 
employed by the University Hospital Centre „Bežanijska 
Kosa“, Department of Coronary Unit, between 28th 
January and 9
th
 of March 2015. Three participants were 
female and two were male. Physicians were interviewed by 
audio recording, using semi-structured interview. Based on 
the analysis of the interviews, seven categories have been 
created.  
A The patients: Coronary Unit has eleven beds. The 
Unit treats around a hundred patients per month. One of 
the interviewed doctors has stressed out that patients 
with acute coronary syndrome are mostly hospitalized 
for three days in the Unit. Patients with more serious 
rhythm abnormalities, ischemic cardiomyopathy with, 
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for example, non-sustained VT or repeated ventricular 
tachycardia are hospitalized longer, up to five or six 
days. All the interviewed medical doctors have noticed 
that there is a correlation between the dynamic of 
admission and season, i.e. atmospheric conditions. In 
winter, the number of admitted patients increases, while in 
summer the number decreases. Also, in fall and spring, 
when atmospheric conditions (temperature, humidity …) 
change significantly, the number of hospitalized patients is 
higher. In Coronary Unit the admission of patients is 
mainly based on the following diagnosis: acute coronary 
syndrome; patients with ST and non-ST elevated 
myocardial infarction; supraventricular arrhythmias type 
tachyarrhythmia absoluta and ventricular rhythm 
abnormality with heart decompensation symptoms; 
complications of coronary diseases, in terms of dilative 
ischemic cardiomyopathy followed by malignant rhythm 
disorder; lung edema, embolism, state of shock of various 
etiology. According to Journal of the American College of 
Cardiology (JACC) guidelines for the management of 
patients with atrial fibrillation, amiodarone should only be 
used after consideration of risks and when other agents 
have failed or are contraindicated because of its potential 
toxicities.  
B Drug preparation: Amiodarone is mainly diluted 
in 5% glucose „even for diabetics, because it is noticed 
that prepared in such way it reacts protectively on veins 
due to its negative influence on venous system and 
development of thrombophlebitis. Very rarely, for 
diabetics with irregular diabetic condition and with 
significantly expressed hyperglycemia we are diluting 
amiodarone in physiological solution.‟(4) According to 
guidelines and summary of drug characteristics, diluting 
amiodarone in physiological solution is not allowed 
because amiodarone and physiological solution are 
incompatible. 
C Drug availability and price: All participants 
point out that the price of amiodarone is not a 
determining fact in administration especially emphasizing 
that „we are using it because we have it.‟ (2) Also, they 
stress that „the choice of antiarrhythmic drugs which you 
have is something that the management of the institution 
may afford you, so probably the price of antiarrhythmic 
drug is in these regards determining, but it is not a 
determining factor for doctor's selection, doctor will 
decide and select something which he sees as the best 
choice for his patient. “(3) However, participants are 
stressing that there is a problem of availability of other, 
alternative drugs. “We do not have any other serious 
antiarrhythmic drugs except amiodarone for parenteral 
use for such kind of arrhythmias.” (5) “Shortage of the 
wider palette of antiarrhythmics leads us to use 
amiodarone very often... For supraventricular rhythm 
disorders, adenosine should absolutely be the first choice, 
and we use it, but it is limited.”(4) “Adenosine we have, 
but it is very expensive. For supraventricular arrhythmia 
we are using mainly Isoptine
®
-verapamil, when we are 
not using amiodarone. And some drugs such are bretilium 
and some even better antiarrhythmics for malignant 
rhythm disorders we don't have.”(5) “Dronedarone we 
don't have. Or even some other drugs, maybe adenosine, 
which we should use in my opinion. These are drugs which 
are not used by routine, they are more expensive and 
simply we don't have them in Coronary Unit available for 
the reaction in particular moment.” (3) One of the reasons 
why amiodarone is often used is that the doctors have 
experience working with it. “We have a lot of positive 
experience working with it” (3) and because it is 
comfortable for use. “The majority of the arrhythmias 
might be treated by amiodarone so its use is the most 
comfortable in Coronary Unit.” (5) In accordance with the 
above mentioned, the lack of other antiarrhythmics may be 
a reason for more frequent although unjustified 
amiodarone administration. 
D Administered dose: In Coronary Unit amiodarone 
is most often administered parenterally, first by bolus and 
afterwards by infusion. Peripheral vein is used for 
application, not the central one. “I think that in 90% of 
cases we are using peripheral vein. Central vein we use 
very rarely because patients don't require central vein 
puncture, that's the first reason, and the second is that our 
patients are very often decompensated, so it is very 
difficult to lay the patient on a flat, it is very difficult to 
punctuate the central vein.” (5) Furthermore, they consider 
that “all of our patients simply don't have central vein.” (1) 
Related to administered dose of drug all participants are 
stressing that “Mainly we are giving to the all patients 
same dose, minimal one.” (1) “We are giving one bolus 
of hundred and fifty milligrams, which means one 
ampoule, after that we are applying infusion. We apply 
infusion beside per os therapy, achieving of the maximum 
dosage of one thousand and two hundred milligrams 
amiodarone daily.” (4) 
In extreme cases, a higher dose of amiodarone is 
administered “if the patient is extremely overweight and 
has huge body mass.” (5) The duration of amiodarone 
administration is related to clinical outcome, “referring to 
ECG.” (2) All participants are intended to use amiodarone 
as shortly as possible, until achieving the desired effects 
and in order to reduce adverse effects caused by usage of 
amiodarone. “I rarely keep patient on the therapy with 
amiodarone in some longer period of time.” (5) According 
to the summary of drug characteristics, amiodarone must 
be administered through a central vein, except in cases of 
cardiopulmonary resuscitation in the event of cardiac arrest 
caused by ventricular fibrillation resistant to external 
electric shock, when due to inaccessibility of the central 
vein, peripheral veins can be used. 
E Systemic side effects: Participants have pointed 
out systemic side effects which they have noticed in the 
Coronary Unit, as well as procedure during the occurring 
such side effects. The most often side effects are: thyroid 
malfunction, cornea deposits, extension of QT interval, 
hepatotoxic effect, photosensitivity with skin changes. 
Literature data mention lung fibrosis as one of the 
possible side effects in acute amiodarone administration 
although none of the doctors came upon this side effect. 
Amiodarone effects on thyroid, regarding hypo- or 
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hyperthyreosis, are often seen. “I have to say that almost 
50% of patients who I‟m treating with heart insufficiency 
and with dilative cardiomyopathy in some period used to 
have either hypo- or hyperthyreosis. Since they had 
malignant ventricular rhythm disorder and since the 
majority of those patients are having defibrillator, in 
consultation with endocrinologist, we have never, or 
rarely, in 10% of patients, we have excluded amiodarone 
when they had thyrotoxicosis. We have reduced the dose 
of amiodarone to one hundred milligrams per day, five 
days a week, and we have tried to resolve a problem 
with thyroid by application of thyro-suppressive therapy 
or by substitutional therapy”. (4) In a case of cornea 
deposits “ophthalmologist assesses are the deposits 
significant and is it necessary to exclude amiodarone 
from the therapy. But if the treatment without amiodarone 
is impossible, we are just temporarily ceasing with 
amiodarone. And we are trying to proceed with some 
other antiarrhythmic.” (2) In case of QT interval extension 
“over 500 milliseconds, or if significant bradycardia or 
conductivity disorder on a level of AV node, such as 
second or third degree AV block, occurs we are absolutely 
excluding amiodarone. This is ultimate indication to stop 
the therapy with amiodarone.” (4) “Photosensitivity with 
skin hyperpigmentation is noticed only in amiodarone long 
term usage, not in acute administration.” (4) Hepatotoxicity 
is very difficult to determine because “we are not certain 
that if patient has ischemic liver or it is a consequence of 
amiodarone use or some synergistic reaction with some 
other drugs, so we cannot give the precise answer. We 
are seeing such patients, but we don‟t know the real 
reason for this. Very often we have patients with 
increased AST and ALT markers of liver necrosis. Even 
if significant numbers of patients have liver ischemia we 
cannot say for sure is it ischemic hepatitis or side effect 
of amiodarone. Those patients are in very bad condition 
and they are admitted to Coronary Unit critically ill.” 
(5) Since the majority of patients in Coronary Unit are 
in critical condition tests related to condition of the 
thyroid, liver, lungs are not performed immediately but 
upon improvement of the patient condition. “I mandatorily 
advise to perform AST and ALT tests, as well as lung‟s X-
ray.” (2) In case of side effects and cessation of 
amiodarone application, the most common choice is beta 
blocker or Dilacor
®
.  
F Local side effects: All participants mentioned 
local adverse events. “I have to say that almost thirty 
percent of patients in Coronary Unit suffer from some 
kind of thrombophlebitis.” (4) The reason for this may 
be found in infusion of amiodarone as well as application 
and infusion preparation. The problem caused by 
amiodarone itself is “amiodarone, followed by high 
concentrated glucoses, is very aggressive agent and 
probably damages veins”, (1) or happens “due to quick 
application of infusion.” (2) One physician pointed out that 
the problem may be “not sufficient monitoring by medical 
nurses in Coronary Unit.” (3) Injection itself may be a 
problem, especially if the patient is older with weak blood 
vessel and if infusion takes too long. The participants 
pointed out that this local adverse reaction may be 
avoided by using the central vein for infusion instead of 
peripheral, which is mainly used at the moment. In case 
of obvious local side effects the most often response is 
“we are replacing cannula, in fact we are changing the 
position of cannula.” (2) “We are changing place of 
injection or if possible we are shifting to per os use.” (5) 
Concerning thrombophlebitis, no therapy is applied except 
for placing of compresses. 
G Inappropriate use: Four out of five participants 
consider that inappropriate use is very rare. “The fact is 
that we don‟t have huge choice of antiarrhythmics and 
whenever we are applying amiodarone, we are applying 
that due to obvious reasons.” (4) One out of five 
participants thinks that it is very often used 
inappropriately. “Very often amiodarone is used as the 
first antiarrhythmic, even if it is not necessary. 
Primarily, I think on supraventricular arrhythmia where 
we may practically use calcium antagonist, so I think 
that inappropriate application in Coronary Unit is 
present. I have experienced that in supraventricular 
arrhythmias, which may be simply treated by other 
antiarrhythmic, which has less complications and side 
effects.” (5) All participants have emphasized that 
amiodarone is generally used inappropriately when it is not 
necessary to convert the patient into sinus rhythm, but only 
to calm down heart rate, and a lot of physicians are already 
using this approach. The participants also gave their 
recommendations for reducing inappropriate use of 
amiodarone. They state that guidelines should be followed 
more carefully, and more frequent educations/trainings 
should be held. “Education of the doctors has to be focused 
on not to be scared of arrhythmias. Amiodarone is in fact a 
good medicine if it is applied in proper indications.” (4) 
Participants: 1-male, 42 years old; 2-female, 40 
years old; 3-female, 43 years old; 4-female, 52 years 
old; 5-male, 43 years old 
Besides interview with physicians operating in 
Coronary Care Unit, medical records of seven patients 
treated by amiodarone have been observed. Of the total 
number of patients, six were male and one was female, age 
range from 25 to 82. Six out of seven patients have been 
treated with amiodarone parenterally and one patient 
received amiodarone per os. Diagnoses on admission were: 
Tachyarrhythmia absoluta; Tachyarrhythmia absoluta with 
decompensation of newfound dilated cardiomyopathy; 
Fibrillation Atriorum paroxysmal (Myopericarditis virosa 
suspecta); ST elevation myocardial infarction infer 
posterior, upon admission to the Coronary Unit the patient 
developed primary ventricular fibrillation; decompensating 
of chronic dilated valvular cardiomyopathy and terminal 
condition of heart failure. Retention period in Coronary 
Care Unit was up to five days. Two cases ended fatally, 
while others were converted into sinus rhythm within 48 
hours. Amiodarone was indeed applied as a bolus followed 
by infusion, at the dose of two plus four ampoules. It was 
noted that amiodarone is often dissolved in physiological 
solution instead of 5% glucose solution, which is 
mandatory according to Summary of Product 
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Characteristics (SPC). It was observed that even with the 
same patient amiodarone was occasionally diluted in a 
glucose solution and occasionally in physiological solution. 
When asked to explain this discrepancy, physicians could 
not give an appropriate answer. In some cases amiodarone 
was combined with Dilacor
®
, usually accompanied by 
anticoagulation therapy and IV diuretics. One patient‟s 
lab results have showed elevated values of thyroid 
hormones, forcing amiodarone exclusion from the 
therapy. In consultation with the endocrinologist, thyroid 
suppressive therapy was introduced. Other adverse events 
were not observed.  
Finally, the third part of the study was visiting 
hospitalized patients together with physicians. Patients‟ 
therapy is prescribed exclusively by doctors employed 
in the Coronary Care Unit Department. Twenty four 
hours a day the attending physician is present in order to 
react immediately when it comes to hospitalization. Six 
out of eleven beds in Coronary Care Unit were occupied. 
All patients were on 24-hour ECG monitoring. Three out 
of six patients had visible thrombophlebitis caused by 
amiodarone infusion. 
Discussion  
From our results, we noticed that amiodarone is often 
inappropriately used for supraventricular rhythm 
disturbances. It is used for frequency correction. If a 
patient suffers from atrial fibrillation and we do not 
expect sinus rhythm to be reached, and there is a rapid 
chamber activity, usually another reason is present 
(worsening of heart function, heart failure) due to which 
the patient is in absolutes. In such cases, correction is 
achieved by solving heart failure problem, not by 
amiodarone administration. When the probability of 
converting a patient into sinus is minimum, amiodarone 
should not be administered, but this was not always the 
case. Such patients are usually on long-term amiodarone 
administration which is practically contraindicated and 
many of adverse events may occur. The Journal of the 
American College of Cardiology (JACC) in its guidelines 
for the management of patients with atrial fibrillation, 
states that amiodarone should only be used after 
consideration of risks and when other agents have failed 
or are contraindicated because of its potential toxicities 
[20]. According to data collected during interviews, this 
was not always the case. Amiodarone was sometimes 
administered as first line antiarrhythmic, not considering 
a less toxic solution. Also, the participants were not 
aware of the fact that amiodarone is incompatible with 
physiological solution. Insight into patient files shows 
that even with the same patient, amiodarone was 
sometimes diluted in physiological solution and other 
times it was diluted in in 5% glucose. Analysis of patient 
medical files has showed that amiodarone was not 
prescribed inappropriately; it was prescribed in proper 
indication and in proper dose. As excuse for unjustified 
administration, the interviewed doctors said that 
amiodarone does not have too many significant adverse 
effects and it is useful and provides safety and comfort. 
Besides, Coronary Unit does not have wide range of 
antiarrhythmics available and which may be a better 
solution than amiodarone in patient treatment. The reason 
for unjustified administration of amiodarone may be 
found in lack of knowledge and awareness of medical 
staff about indications for use and adverse events. Thus, 
training of medical staff has to be implemented more 
frequently in order to overcome this problem. However, 
according to some data, amiodarone is being used 
inappropriately in other countries as well. For example, 
amiodarone is approved by the US Food and Drug 
Administration only for refractory ventricular arrhythmias 
but it is one of the most frequently prescribed 
antiarrhythmic medications in the United States
 
[21]. 
Research conducted in Poland has shown that amiodarone 
was potentially inappropriately prescribed in 7.47% of 
cases in geriatric patients [16] and a survey taken in Italy 
has shown that amiodarone was potentially inappropriately 
prescribed in 19.1% cases in elderly patients with 24.9% of 
potentially inappropriate doses [17]. 
Discussion about obtained results was based on two 
facts. First, the research was carried out in the 
University Hospital Centre “Bezanijska Kosa” which is 
a tertiary health institution. We could expect less 
inappropriate use than in other health care institutions 
because medical staff has higher expertise. Considering 
the fact that the drug was developed in 1961 and there 
are precise guidelines for its use as well as numerous 
scientific papers which are publishing unjustified 
administration and adverse events
 
[22], inappropriate 
use should be minimum. Secondly, all interviewed 
doctors said that they have experience with amiodarone 
administration. 
Unjustified administration of amiodarone in Coronary 
Care Unit is rare, as considered by the majority of the 
interviewed doctors. Some of the interviewed doctors 
indicated that one of the reasons of unjustified 
administration is lack of other antiarrhythmics. However, 
the rational application of the drug would reduce costs 
and thus procurement of other medicines would be 
possible. Some studies have confirmed that costs increase 
by unjustified application of the drugs
 
[23]. 
Conclusion 
Research conducted at Coronary Care Unit of University 
Hospital Centre “Bezanijska Kosa” pointed to existence 
of inappropriate use of amiodarone in some cases. There 
are two reasons for this occurrence. The first one is due to 
objective reasons. The Coronary Unit has a sufficient 
number of antiarrhythmics available and amiodarone is 
always accessible. How often amiodarone was prescribed 
due to lack of other agents could not be determined. The 
nature of the second reason is subjective. Doctors opt for 
amiodarone because it is secure and convenient. This 
problem may be alleviated by strictly applying the 
scheduled treatment protocol.  
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Finally, we may conclude that besides the lack of 
other antiarrhythmics available, amiodarone was mostly 
inappropriately prescribed due to the lack of familiarity 
with its side effects. Also, physicians were not aware 
that amiodarone is incompatible with physiological 
solution and they were often administering it as a first 
line antiarrhythmic, not considering another, less toxic 
solution. Thus, physicians should follow guidelines 
when prescribing the drug and additional education 
should be implemented.   
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